Two Sigma Investments
GANX icon

Two Sigma Investments’s Gain Therapeutics GANX Stock Holding History

Two Sigma Investments’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,467
Closed -$106K – 3276
2021
Q4 		$106K Buy
+19,467
New +$134K ﹤0.01% 4050

Other funds holding GANX

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments's GANX Position: Q1 2022 in Review

Two Sigma Investments sold out of Gain Therapeutics (GANX) in Q1 2022, closing a stake of 19,467 shares — an estimated $106K sold.

Two Sigma Investments first reported a position in GANX in Q4 2021 and held it in 1 quarter. The position peaked at $106K in Q4 2021. 16 funds tracked by Wall St. Rank hold GANX as of Q1 2022.

  • Two Sigma Investments reported no remaining Gain Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Two Sigma Investments sold 19,467 Gain Therapeutics shares in Q1 2022, an estimated $106K.
  • Two Sigma Investments first reported a position in Gain Therapeutics in Q4 2021 and held it in 1 quarter.
  • Two Sigma Investments's Gain Therapeutics position peaked at $106K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2022.

Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.